FDA Approved: DIOVAN — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for DIOVAN (valsartan) submitted by Novartis Pharmaceuticals Corporation, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Heart Failure
• Hypertension
• Postmyocardial Infarction

Drugs mentioned

• DIOVAN (valsartan)

Snippet

SUPPL AP for DIOVAN (VALSARTAN)